INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonic Automotive, Inc. - SAH

NEW YORK, October 24, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Sonic Automotive, Inc. (“Sonic Automotive” or the “Company”) (NYSE: SAH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Sonic Automotive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 23, 2025, Sonic Automotive reported its financial results for the third quarter of 2025.  Among other items, Sonic Automotive reported a 33% decline in net income, which the Company attributed to a significant increase in medical expenses and a higher effective income tax rate during the quarter. 

On this news, Sonic Automotive’s stock price fell $12.36 per share, or 15.88%, to close at $65.48 per share on October 23, 2025

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming Deadlines - MLTX

NEW YORK, October 23, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“Moonlake” or the “Company”) (NASDAQ: MLTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Moonlake and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 15, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Moonlake securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On September 28, 2025, MoonLake reported disappointing results from its Phase 3 VELA trials evaluating the efficacy and safety of sonelokimab.  One trial failed to meet its primary endpoint, while the other showed only modest gains versus placebo. 

Following this news, MoonLake’s stock price fell $55.75 per share, or 89.93%, to close at $6.24 per share on September 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Baxter International, Inc. of Class Action Lawsuit and Upcoming Deadlines - BAX

NEW YORK, October 23, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Baxter and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 15, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Baxter securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On July 31, 2025, Baxter announced that it had decided to “voluntarily and temporarily pause shipments and planned installations of the Novum LVP”, a medical device used for the controlled delivery of intravenous fluids, and that the Company was “unable to currently commit to an exact timing for resuming shipment and installation for Novum IQ LVPs.”  Baxter stated that they had offered “customers the option of our Spectrum infusion pump as an alternative” and that the Company’s low-end guidance assumes that the Company does not resume shipments for Novum LVPs before the end of the year. 

On this news, Baxter’s stock price fell $6.29 per share, or 22.4%, to close at $21.76 per share on July 31, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mr. Cooper Group Inc. - COOP

NEW YORK, October 23, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Mr. Cooper Group Inc. (“Mr. Cooper” or the “Company”) (NASDAQ: COOP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Mr. Cooper and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

The offering materials for the Merger (the “Offering Materials”) stated that the Merger will potentially “generate $100 million in additional pre-tax revenue from higher recapture rates and attaching Rocket’s title, closing and appraisal services to Mr. Cooper’s existing originations,” “provide the combined company with $500 million in run-rate pre-tax cost savings from streamlining operations, corporate expense and technology investments,” and help the combined Company to “drive significant incremental client acquisition and accelerate Rocket’s origination-servicing flywheel.”  Further, the Offering Materials stated that the Merger will be “accretive to Rocket’s earnings per share immediately after closing, and mid-teens accretive on a percentage basis to Rocket’s estimated 2026 earnings per share.”  On September 30, 2025, the day before the Merger closed, the Federal Trade Commission (“FTC”) announced that it sued Zillow Group, Inc. and Zillow, Inc. (collectively, “Zillow”), and Rocket subsidiary Redfin Corporation (“Redfin”) over an unlawful agreement that eliminates Redfin as a competitor in the market for placing advertising of rental housing on internet listing services.  In its lawsuit, the FTC alleges that in exchange for a $100 million payment and other compensation from Zillow, Redfin agreed to end its contracts with advertising customers and help Zillow take over that business, stop competing in the advertising market for multifamily properties for up to nine years, and to serve merely as an exclusive syndicator of Zillow listings, making Redfin sites effectively a copy of the listings that appear on Zillow’s sites. 

Since the closing of the Merger on October 1, 2025, Rocket’s share price has declined significantly.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NuScale Power Corporation - SMR

NEW YORK, October 23, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  NuScale Power Corporation (“NuScale” or the “Company”) (NYSE: SMR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether NuScale and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 21, 2025, Citigroup downgraded NuScale to Sell/High Risk from Neutral/High Risk, citing “competition from new entrants” and noting that “a binding customer contract remains elusive”.  Citigroup further asserted that “the company trades at a stretched valuation” and that “further sale of interest by Fluor”—a major NuScale shareholder—“weighs on the stock”. 

Following the downgrade, NuScale’s stock price fell $9.49 per share, or 21.47%, over the following two trading sessions, to close at $34.72 per share on October 22, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alector, Inc. - ALEC

NEW YORK, October 23, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Alector, Inc. (“Alector” or the “Company”) (NASDAQ: ALEC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Alector and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 21, 2025, Alector issued a press release “announc[ing] results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).”  The press release disclosed that latozinemab “did not meet the clinical co-primary endpoint of slowing FTD-GRN progression,” and that “the secondary and exploratory endpoints, such as fluid biomarkers and volumetric magnetic resonance imaging (vMRI), demonstrated no treatment-related effects on FTD-GRN.” 

On this news, Alector’s stock price fell $1.60 per share, or 49.84%, to close at $1.61 per share on October 22, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT

NEW YORK, October 23, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Arcturus Therapeutics Holdings Inc.  (“Arcturus” or the “Company”) (NASDAQ: ARCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Arcturus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 22, 2025, Arcturus issued a press release “announc[ing] interim results from its ongoing Phase 2 clinical trial of ARCT-032, an investigational inhaled mRNA therapy for people with cystic fibrosis.”  The press release disclosed that patients in the trial had not shown a meaningful improvement in forced expiratory volume for one second, or FEV1, a key test for the health of cystic fibrosis patients. 

On this news, Arcturus’s stock price fell $11.62 per share, or 50.17%, to close at $11.54 per share on October 22, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jefferies Financial Group Inc. - JEF

NEW YORK, October 21, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Jefferies Financial Group Inc. (“Jefferies” or the “Company”) (NYSE: JEF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Jefferies and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2025, The Wall Street Journal published an article entitled “Auto Supplier First Brands Files for Bankruptcy Amid Accounting Questions,” reporting that “[t]he closely held company’s lenders and independent board directors are now probing whether First Brands made misrepresentations in its financial reporting” and that “First Brands relied heavily on accounts-receivable-backed financing, supplying automotive products to customers on delayed payment terms and borrowing from outside investors against the billed receivables.”  Then, on October 8, 2025, The Wall Street Journal further reported, in an article entitled “First Brands Bankruptcy Damage Spreads to Jefferies UBS,” that Jefferies “said funds run by an asset-management unit, Point Bonita Capital, are owed around $715 million from companies that bought First Brands’ parts.”  

On this news, Jefferies’ stock price fell $4.66 per share, or 7.88%, to close at $54.44 per share on October 8, 2025. 

The following day, Reuters disclosed that “The U.S. Department of Justice has launched an inquiry into the collapse of bankrupt auto parts maker First Brands Group” and that “[t]he Justice Department is probing the company and its dealings with creditors.” 

On this news, Jefferies’ stock price fell another $1.43 per share, or 2.63%, to close at $53.01 per share on October 9, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Homes Group, Inc. - UHG

NEW YORK, October 21, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  United Homes Group, Inc. (“UHG” or the “Company”) (NASDAQ: UHG).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether UHG and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 20, 2025, six UHG board members resigned following the refusal of Executive Chairman Michael Nieri to step down from his role at the Company and forgo any future compensation.  Nieri’s refusal to agree to those conditions followed a strategic review of UHG’s business by a special committee of independent directors, who unanimously concluded that “continuing to execute on the Company’s strategic plan as an independent, public company is in the best interests of the Company and its stockholders at this time.” 

On this news, UHG’s stock price fell $2.24 per share, or 52.46%, to close at $2.03 per share on October 20, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

NEW YORK, October 21, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Exelixis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On July 28, 2025, Exelixis issued a press release “report[ing] financial results for the second quarter of 2025” and “provid[ing] an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.”  Among other items, Exelixis reported that net product revenues for cabozantinib were approximately 2% below the consensus estimate of $531.3 million.  Exelixis also disclosed that “[b]ased on our evaluation of emerging data from the phase 2 portion of the STELLAR-305 study in advanced squamous cell carcinoma of the head and neck, emerging competition in this indication and assessment of other potentially larger commercial opportunities, we have made the decision not to proceed to the phase 3 portion of the trial.”   

On this news, Exelixis’s stock price fell $7.45 per share, or 16.78%, to close at $36.94 per share on July 29, 2025. 

Then, on October 20, 2025, Exelixis issued a press release “announc[ing] detailed  results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC).”  The press release disclosed that while the drug achieved one of its dual primary endpoints, showing a modest Overall Survival gain, the second endpoint for the non-liver metastases subgroup remains immature.  The press release also disclosed that a high incidence of severe side effects raised safety concerns. 

On this news, Exelixis’s stock price fell $4.71 per share, or 12%, to close at $34.54 per share on October 20, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of American Battery Technology Company - ABAT

NEW YORK, October 20, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  American Battery Technology Company (“American Battery” or the “Company”) (NASDAQ: ABAT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether American Battery and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 15, 2025, American Battery disclosed in a filing with the U.S. Securities and Exchange Commission that the U.S. Department of Energy (“DoE”) had terminated its grant for the construction of a commercial scale facility for the manufacturing of battery cathode grade lithium hydroxide.  Under the grant, the DoE would have contributed $57.7 million towards the facility, while the Company would have put in an equal amount. 

On this news, American Battery’s stock price fell $6.48 per share, or 57.19%, over the following three trading sessions, closing at $1.85 per share on October 17, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jumia Technologies AG - JMIA

NEW YORK, October 20, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Jumia Technologies AG (“Jumia” or the “Company”) (NYSE: JMIA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Jumia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 17, 2025, Aletheia Capital downgraded Jumia to Sell from Buy, citing concerns about Jumia’s net working capital position.  The Aletheia analyst considered Jumia’s improvements in the metric to be temporary and unsustainable, and also noted that Jumia’s stock is priced higher than peer e-commerce stocks in terms of enterprise value-to-sales ratio. 

On this news, Jumia’s American Depositary Receipt (“ADR”) price fell $1.13 per ADR, or 9.51%, to close at $10.75 per ADR on October 17, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

NEW YORK, October 20, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether I-Mab and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 16, 2025, I-Mab issued a press release “announc[ing] its new business model[.]”  I-Mab said that it “intends to partner with leading innovators to identify and accelerate high-value assets” and “will utilize a ‘hub-and-spoke’ model to crate and advance specialized subsidiary companies (spokes) which maintain operational focus and agility.”  I-Mab also “announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX)” and to change its name to NovaBridge Biosciences. 

Following these announcements, I-Mab’s American Depositary Receipt (“ADR”) price fell $0.79 per ADR, or 12.04%, to close at $5.77 per ADR on October 17, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

NEW YORK, October 20, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Protalix BioTherapeutics, Inc. (“Protalix” or the “Company”) (NYSE: PLX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Protalix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

 [Click here for information about joining the class action]

On October 17, 2025, Protalix and Chiesi Global Rare Diseases, Protalix’s partner in “the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system”,   issued a press release “acknowledg[ing] that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the request to approve the dosing regimen of 2 mg/kg body weight infused every 4 weeks (E4W) for Elfabrio (pegunigalsidase alfa, in addition to the currently approved dosing regimen of 1 mg/kg body weight infused every 2 weeks (E2W).” 

On this news, Protalix’s stock price fell $0.54 per share, or 22.5%, to close at $1.86 per share on October 17, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Fortress Biotech Inc. (“Fortress” or the “Company”) (NASDAQ: FBIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Fortress and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 1, 2025, Fortress and its subsidiary, Cyprium Therapeutics, Inc., announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration in connection with the New Drug Application for CUTX-101.  Fortress disclosed that the “CRL noted cGMP [Current Good Manufacturing Practice] deficiencies had been observed at the facility where CUTX-101 is manufactured.” 

On this news, Fortress’s stock price fell $1.14 per share, or 30.81%, to close at $2.56 per share on October 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Coherent Corp. - COHR

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Coherent Corp. (“Coherent” or the “Company”) (NYSE: COHR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Coherent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 13, 2025, Coherent issued a press release “announc[ing] that it has entered into a definitive agreement to sell its Aerospace and Defense business to Advent, a leading global private equity investor, for $400 million.”  Coherent said that “[p]roceeds will be used to reduce debt[.]” 

On this news, Coherent’s stock price fell $22.36 per share, or 19.61%, to close at $91.65 per share on August 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Palantir Technologies Inc. - PLTR

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Palantir Technologies Inc.  (“Palantir” or the “Company”) (NASDAQ: PLTR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Palantir and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 3, 2025, media outlets reported that an internal U.S. Army memo described the NGC2 platform – a battlefield communication system developed by Palantir and Anduril Industries – as a “very high risk” due to security vulnerabilities that could allow adversaries to gain “persistent undetectable access” to the system. 

On this news, Palantir’s stock price fell $13.98 per share, or 7.47%, to close at $173.07 per share on October 3, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Freshpet, Inc. - FRPT

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Freshpet, Inc. (“Freshpet” or the “Company”) (NASDAQ: FRPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Freshpet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 8, 2025, Bank of America downgraded Freshpet to Neutral from Buy and cut its price objective to $60 from $81, saying demand for fresh pet food has weakened as consumers rein in spending and pet adoption rates slow. 

Following the downgrade, Freshpet’s stock price fell $3.36 per share, or 6.36%, to close at $49.51 per share on October 8, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stride, Inc. - LRN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Stride and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 14, 2025, Simply Wall St. published a report stating that the Gallup-McKinley County Schools Board of Education had filed a complaint against Stride, alleging fraud, deceptive trade practices, systemic violations of law, and intentional and tortious misconduct, including inflating enrollment numbers by retaining “ghost students” on rolls to secure state funding per student and ignoring compliance requirements, including background checks and licensure laws for its employees. 

Following this news, Stride’s stock price fell $18.60 per share, or 11.75%, to close at $139.76 per share on September 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 24, 2025, Acadia issued a press release “announc[ing] top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS).”  The press release disclosed that the drug “did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was there separation from placebo on any secondary endpoint.”  Acadia’s Head of Research and Development stated that, “given these results, we do not intend to investigate intranasal carbetocin any further.” 

On this news, Acadia’s stock price fell $2.34 per share, or 9.92%, to close at $21.26 per share on September 24, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.